KR102643628B1 - A composition for improving milium comprising lactic acid bacteria - Google Patents

Abstract

The present invention provides a cosmetic composition or external skin composition for improving milia or keratoma containing lactic acid bacteria as an active ingredient.

Description

Composition for improving milia containing lactic acid bacteria {A COMPOSITION FOR IMPROVING MILIUM COMPRISING LACTIC ACID BACTERIA}

The present invention relates to a composition for improving milia containing lactic acid bacteria as an active ingredient, and can be used for various purposes such as cosmetic compositions and external skin preparations.

As the average lifespan increases due to the development of medical technology and the standard of living improves due to the rise in national income, modern people's interest in their health and appearance is increasing, and they are becoming more interested in taking care of their appearance.

As the importance of human relationships increases due to the development of modern society, a person's appearance becomes an important factor in determining first impressions.

As social interest in clean and healthy skin to maintain a beautiful appearance increases, methods to care for the skin are being developed.

Skin disorders in exposed areas of the human body are combined with cosmetic aspects and can cause psychological anxiety, rejection of social life, mental stress, and reduce the quality of life.

Representative examples of skin abnormalities include skin diseases such as milia.

The above-mentioned milia (milium), also known as millet, are small white or yellow ball-shaped pockets of about 1 mm in size located in shallow areas of the skin and are filled with dead skin cells.

Milia are divided into primary milia and secondary milia depending on the cause. Primary milia are naturally occurring milia that commonly occur on the face, especially the cheeks and eyelids, and occur at any age.

Secondary lesions have the same appearance as primary lesions and occur where the skin has been damaged. There is no significant difference in the incidence of the disease between men and women, and it is a benign skin tumor that is mainly treated for cosmetic purposes, using an extruder or laser to expel dead skin cells inside the sac.

As such, there is currently no fundamental treatment for skin diseases such as milia, so people are relying on procedures using lasers, etc.

Meanwhile, in the cosmetics industry, many products using natural products are being developed to reduce skin irritation caused by various chemicals.

Not only do natural ingredients have fewer side effects on the skin, but their development value as cosmetic raw materials is increasing as consumers' response to cosmetics using natural ingredients has recently increased.

Therefore, the present inventors sought to discover new materials for improving milia using natural raw materials that are harmless to the human body and utilize them for skin care purposes.

(Patent Document 1) Republic of Korea Patent Publication No. 2019-0062021
(Patent Document 2) Republic of Korea Patent No. 10-1991894

The present invention is intended to solve the above-mentioned problems, and the purpose of the present invention is to confirm the skin disease improvement effect of lactic acid bacteria and thereby provide a cosmetic composition with excellent biosafety.

According to one aspect of the present invention, a cosmetic composition for improving milia or keratoma containing lactic acid bacteria as an active ingredient is provided.

In one embodiment, the lactic acid bacteria are Lactobacillus genus, Streptococcus genus, Lactococcus genus, Enterococcus genus, Pediococcus genus, Leuconostoc ), Weissella , and Bifidobacterium may be selected from the group consisting of strains of the genus.

In one embodiment, the Lactobacillus genus strains include Lactobacillus salivarius, Lactobacillus acidophilus , Lactobacillus brevis , Lactobacillus rhamnosus , and Lactobacillus rhamnosus. Bacillus plantarum , Lactobacillus helveticus, Lactobacillus fermentum , Lactobacillus paracasei , Lactobacillus casei , Lactobacillus delbruecki ( Lactobacillus delbrueckii ), Lactobacillus reuteri , Lactobacillus buchneri, Lactobacillus gasseri, Lactobacillus johonsonii , and Lactobacillus kefir . One or more may be selected from the group consisting of:

In one embodiment, the lactic acid bacteria may be composed of two or more mixed strains.

In one embodiment, the cosmetic composition may further include a skin emollient.

According to another aspect of the present invention, a composition for external skin application for improving milia or ducts containing lactic acid bacteria as an active ingredient is provided.

In one embodiment, the lactic acid bacteria are Lactobacillus genus, Streptococcus genus, Lactococcus genus, Enterococcus genus, Pediococcus genus, Leuconostoc ), Weissella , and Bifidobacterium may be selected from the group consisting of strains of the genus.

In one embodiment, the lactic acid bacteria may be composed of two or more mixed strains.

According to the present invention, the cosmetic composition or external skin composition contains lactic acid bacteria as an active ingredient, so it effectively acts on the subcutaneous dead skin cells of milia and has excellent biosafety.

The effects of the present invention are not limited to the effects described above, and should be understood to include all effects that can be inferred from the configuration of the invention described in the detailed description or claims of the present invention.

The terms used in this specification are general terms that are currently widely used as much as possible while considering the function in the present invention, but this may vary depending on the intention or precedent of a person skilled in the art, the emergence of new technology, etc. In addition, in certain cases, there are terms arbitrarily selected by the applicant, and in this case, the meaning will be described in detail in the description of the relevant invention. Therefore, the terms used in the present invention should be defined based on the meaning of the term and the overall content of the present invention, rather than simply the name of the term.

Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by a person of ordinary skill in the technical field to which the present invention pertains. Terms defined in commonly used dictionaries should be interpreted as having meanings consistent with the meanings they have in the context of the related technology, and unless clearly defined in the present application, should not be interpreted in an idealized or excessively formal sense. No.

The numerical range includes the values defined in the range above. Every maximum numerical limit given throughout this specification includes all lower numerical limits as if the lower numerical limit were explicitly written out. Every minimum numerical limit given throughout this specification includes every higher numerical limit as if such higher numerical limit was clearly written. All numerical limits given throughout this specification will include all better numerical ranges within the broader numerical range, as if the narrower numerical limits were clearly written.

Hereinafter, examples of the present invention will be described in detail, but it is obvious that the present invention is not limited to the following examples.

According to one aspect of the present invention, a cosmetic composition for improving milia or keratoma containing lactic acid bacteria as an active ingredient is provided.

The cosmetic composition contains natural raw materials rather than chemical ingredients as active ingredients, so it not only has excellent skin improvement effect and biosafety, but also minimizes skin irritation.

The cosmetic composition has various active ingredients contained in lactic acid bacteria and enzymes that effectively act on subcutaneous dead skin cells, thereby providing excellent removal of milia or ductal tumors.

In particular, two or more types of complex lactic acid bacteria can effectively improve skin diseases such as milia by acting on the skin at the same time.

The milia are small cysts filled with keratin on the inside, which may occur near the surface of the skin and may include primary milia and secondary milia.

The syringoma is a small yellow or flesh-colored lump with a diameter of 2 to 3 mm that appears on the skin and is also called an under-eye wart. It is presumed to be a benign tumor caused by changes in the sweat glands in the dermis.

There is no fundamental treatment for the milia or ductal tumors other than treatments using lasers, etc., and the present inventors confirmed that the lactic acid bacteria decompose subcutaneous keratin and effectively relieve symptoms.

The lactic acid bacteria have long played an important role in dairy products such as butter and cheese, and fermented foods using lactic acid bacteria have a unique flavor, excellent preservation properties due to the produced lactic acid, and improved digestibility and absorption by partial decomposition of proteins. , showing nutritional excellence and forming a huge market size.

Nevertheless, there has been no confirmed case of treating or relieving skin diseases such as milia by directly applying the lactic acid bacteria to the skin.

The lactic acid bacteria are bacteria that produce lactic acid by decomposing sugars, and may refer to bacteria that produce more than 50% of lactic acid from commonly consumed sugars and do not cause disease.

The lactic acid bacteria can dissolve the stratum corneum of the skin and effectively remove milia or ducts on the skin surface due to the biological characteristic of producing lactic acid.

The lactic acid bacteria may be dead lactic acid bacteria. The dead lactic acid bacteria cells refer to live lactic acid bacteria that have been killed by heat treatment, etc., and may be in the form of freeze-dried powder, but are not limited to this and can be used in various forms.

The dead lactic acid bacteria cells can easily utilize useful ingredients without being affected by heat or pH, and are not only advantageous for commercialization but also advantageous for maintaining product quality.

The lactic acid bacteria include Lactobacillus genus, Streptococcus genus, Lactococcus genus, Enterococcus genus, Pediococcus genus, Leuconostoc genus, Bycella ( It may be one or more strains selected from the group consisting of strains of the genus Weissella and Bifidobacterium , but is not limited thereto.

The present inventors confirmed that lactic acid bacteria, which are widely known in the art, can effectively alleviate the symptoms of milia or ductal tumors due to certain common biological characteristics for producing lactic acid.

The Lactobacillus genus strain is a bacterium (Gram-positive spore-free bacillus) that produces a large amount of lactic acid by fermenting sugars to obtain energy, and the Lactobacillus strain is Lactobacillus salivarius , Lactobacillus asi. Lactobacillus acidophilus , Lactobacillus brevis , Lactobacillus rhamnosus , Lactobacillus plantarum , Lactobacillus helveticus, Lactobacillus fermentum fermentum ), Lactobacillus paracasei , Lactobacillus casei , Lactobacillus delbrueckii, Lactobacillus reuteri , Lactobacillus buchneri , Lactobacillus One or more may be selected from the group consisting of Lactobacillus gasseri , Lactobacillus johonsonii , and Lactobacillus kefir , but are not limited thereto.

The lactic acid bacteria may be composed of two or more mixed strains.

The lactic acid bacteria may have different useful components or characteristics depending on the type, and the effect of improving skin diseases can be further enhanced by the synergistic activity of two or more mixed strains rather than a single strain.

The cosmetic composition may further include a skin emollient.

The skin emollient is not particularly limited as long as it is an ingredient that softens the skin and dissolves dead skin cells, and includes, for example, urea, gluconolactone, lactobionic acid, glycolic acid, and lactic acid. (lactic acid), salicylic acid, alpha keto-acid, bisabolol, retinol, and capryloyl salicylic acid, isopropylmylic acid One or more may be selected from the group consisting of oil, silicone material, mineral oil, and vegetable oil, but urea is preferably used.

The urea is a skin emollient that softens the skin, and is also called urea. It has moisturizing, keratolytic, and antibacterial effects, so it can be used as an ingredient in external skin preparations.

According to another aspect of the present invention, a composition for external skin application for improving milia or ducts containing lactic acid bacteria as an active ingredient is provided.

The skin external agent refers to an external medication applied to the skin without oral administration or injection, and may be an external liquid, external powder, ointment, hard plaster, etc.

Since the skin external preparation contains lactic acid bacteria as an active ingredient, it can effectively alleviate skin diseases when applied to the surface of milia, etc.

The cosmetic composition or external skin preparation may be formulated by conventional methods. In formulating external skin agents, information disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA can be referred to, and in formulating cosmetic compositions, International cosmetic ingredient dictionary, 6th ed., The cosmetic, Toiletry and Fragrance. Association, Inc., Washington, 1995.

Specifically, the cosmetic composition can be prepared in the form of a general emulsified formulation and solubilized formulation. For example, lotion such as softening lotion or nourishing lotion; Emulsions such as facial lotion and body lotion; Creams such as nutritional cream, moisture cream, eye cream, etc.; essence; cosmetic ointment; spray; gel; pack; sunscreen; makeup base; Foundation, such as liquid type, solid type, or spray type; powder; Make-up removers such as cleansing creams, cleansing lotions, and cleansing oils; Alternatively, it may be formulated as a cleansing agent such as cleansing foam, soap, or body wash, but is not limited to this.

Additionally, the skin external preparation may be formulated as an ointment, patch, gel, cream, or spray, but is not limited thereto.

In each formulation of the cosmetic composition or external preparation, in addition to the above essential ingredients, other ingredients may be appropriately mixed depending on the type of formulation or purpose of use, within the range that does not impair the purpose of the present invention.

The cosmetic composition or external preparation may contain a commonly acceptable carrier, and may be appropriately mixed with, for example, oil, water, surfactant, moisturizer, lower alcohol, thickener, chelating agent, colorant, preservative, fragrance, etc., but is limited thereto. It doesn't work.

The acceptable carrier may vary depending on the formulation. For example, when formulated into ointments, pastes, creams or gels, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or these are used as carrier ingredients. mixtures can be used

When the cosmetic composition or external agent is formulated as a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, or a mixture thereof may be used as a carrier component, and in the case of a spray, chlorofluorocarbons may be used. It may further include propellants such as hydrocarbon, propane, butane or dimethyl ether.

When the cosmetic composition or topical agent is formulated as a solution or emulsion, a solvent, solubilizing agent, or emulsifying agent may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl benzoate, and propylene. Glycol, 1,3-butylglycol oil may be used, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan. there is.

When the cosmetic composition or topical agent is formulated as a suspension, the carrier component includes water, a liquid diluent such as ethanol or propylene glycol, and a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester. Agents such as microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used.

When the cosmetic composition is formulated into soap, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, fatty alcohols, vegetable oils, glycerol, sugars, etc. are used as carrier ingredients. can be used

The cosmetic composition or skin external agent may contain fatty substances, organic solvents, solubilizers, thickeners, gelling agents, softeners, antioxidants, suspending agents, stabilizers, and foaming agents commonly used in the industry, depending on the quality or function of the final product. ), fragrances, surfactants, water, ionic or non-ionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic activators, common in cosmetics. It may additionally contain auxiliaries commonly used in the fields of cosmetology or dermatology, such as any other ingredients used.

However, the auxiliaries and their mixing ratio may be appropriately selected so as not to affect the desirable properties of the cosmetic composition or external skin preparation according to the present invention.

The present invention will be described in further detail through the following examples, but it is obvious that the present invention is not limited by the following examples.

Examples and Comparative Examples

Examples and comparative examples were set as follows to verify the inhibitory effect of lactic acid bacteria on milia and ducts.

In order to clarify that the effect was due to each strain, a single species of each lactic acid bacteria was selected and tested, and the effects were compared after mixing and applying.

For each strain, dead freeze-dried lactic acid bacteria were obtained and used, and in order to ensure the same experimental results, they were formulated under the same conditions except for the presence or absence of the Example and Comparative Example samples.

[Content (parts by weight)] division Example One 2 3 4 5 6 7 8 9 10 Lactobacillus plantarum 15 - - - - - - - 7.5 7.5 Streptococcus thermophilus - 15 - - - - - - 7.5 - Lactococcus lactis - - 15 - - - - - - 7.5 Enterococcus faecalis - - - 15 - - - - - - Pediococcus pentosaceus - - - - 15 - - - - - Leukonostoc Mesenteroides - - - - - 15 - - - - Vicella coriensis - - - - - - 15 - - - Bifidobacterium bifidum - - - - - - - 15 - - urea - - - - - - - - - -

[Content (parts by weight)] division Example 11 12 13 14 15 16 17 18 19 20 Lactobacillus plantarum 7.5 - - - - - 5 - 15 5 Streptococcus thermophilus - 7.5 7.5 7.5 - - 5 - - 5 Lactococcus lactis - 7.5 - - 7.5 7.5 5 - - 5 Enterococcus faecalis 7.5 - 7.5 - 7.5 - - - - - Pediococcus pentosaceus - - - 7.5 - 7.5 - - - - Leukonostoc Mesenteroides - - - - - - - 5 - - Vicella coriensis - - - - - - - 5 - - Bifidobacterium bifidum - - - - - - - 5 - - urea - - - - - - - - 5 5

[Content (parts by weight)] division Comparative example One 2 3 4 5 6 7 8 9 10 Yeast ( Saccharomyces serevisiae) 15 - - - 7.5 7.5 15 - - - Bacillus subtilis - 15 - - 7.5 - - 15 - - Aspergillus oryzae - - 15 - - 7.5 - - 15 - Actinomycetes ( Streptomyces griseus ) - - - 150 - - - - - 15 urea - - - - - - 5 5 5 5

Experimental Example 1: Skin safety test

To verify the skin safety of the examples and comparative examples, MTT assay experiments were performed on fibroblasts (HDF), melanocytes (B16F10), and keratinocytes (HaCaT).

Samples were suspended in purified water at concentrations of 0, 1, 5, 10, 20, 50, and 100 μg/mL, and then cell viability was measured.

Cytotoxicity was performed by modifying Mosmann's method of measuring cell viability using the MTT {3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide} reagent.

Fibroblasts (HDF), melanocytes (B16F10), and keratinocytes (HaCaT) were each distributed in a 96-well plate at a concentration of 1 × 10 ⁴ cells/well and cultured at 37°C and 5% CO ₂ for 48 hours. did.

The culture medium was removed, and the sample was cultured in medium treated at each concentration for 48 hours, then the medium was removed and washed repeatedly with PBS (Phosphate buffered saline).

MTT was dissolved in PBS at 5 mg/mL, 50L was added, and cultured at 37°C and 5% CO ₂ for 48 hours. 100 L of DMSO (dimethyl sulfoxide) was added per well, stirred for 10 minutes, and absorbance was measured at 540 nm.

As a result of the measurement, no cytotoxicity was confirmed at any concentration of the sample. The above results suggest that the sample of the above example is not only harmless to the human body but also has excellent safety to the human body.

Experimental Example 2: Evaluation of milia improvement effect

To evaluate the effect of improving milia, an experiment was conducted as follows.

A total of 124 adult men aged 30 or older with milia on the face were divided into 31 groups of 4 each.

After washing the face every morning and evening for two weeks, the test subject applied the formulated composition to the area where milia occurred and allowed it to be fully absorbed. The degree of improvement in milia was graded with a score, and the average values are shown in Table 4.

The grade was measured using a facial measuring instrument (JANUS equipment) and evaluated according to the following conditions.

The control group used a composition of the same formulation that did not contain the samples of Examples and Comparative Examples.

1 point: No lesion (complete improvement)

2 points: Almost no lesions (great improvement)

3 points: mild (moderate improvement)

4 points: Severity (some improvement)

5 points: Severe (no improvement)

division evaluation value Example 1 2.11 Example 2 2.33 Example 3 2.25 Example 4 2.37 Example 5 2.28 Example 6 2.34 Example 7 2.33 Example 8 2.41 Example 9 1.41 Example 10 1.65 Example 11 1.58 Example 12 1.73 Example 13 1.64 Example 14 1.57 Example 15 1.63 Example 16 1.77 Example 17 1.13 Example 18 1.28 Example 19 1.69 Example 20 0.51 Comparative Example 1 4.37 Comparative Example 2 4.14 Comparative Example 3 4.28 Comparative Example 4 4.64 Comparative Example 5 4.53 Comparative Example 6 4.22 Comparative Example 7 4.17 Comparative Example 8 4.34 Comparative Example 9 4.63 Comparative Example 10 4.57 control group 4.69

Referring to Table 4, the composition containing lactic acid bacteria effectively improved milia, and when two or more lactic acid bacteria were mixed (Examples 9 to 18), the milia alleviating effect was further improved.

In particular, in Examples 19 and 20, in which a skin softener was added, the milia improvement effect was further enhanced compared to the case where only lactic acid bacteria were applied.

On the other hand, in the case of a comparative example in which yeast, Bacillus subtilis, Bacillus aureus, and actinomycete, rather than lactic acid bacteria, were applied, almost no milia relief effect was observed.

The above results suggest that lactic acid bacteria can effectively relieve milia by acting on the skin, and that the milia relieving effect can be further improved when lactic acid bacteria are mixed or applied together with a skin emollient.

Experimental Example 3: Evaluation of the effect of improving Hangwanjong

124 adult men over 30 years of age with facial ductoma were divided into 31 groups of 4 each, and the degree of improvement was evaluated in the same manner as in Experimental Example 2 (Table 5).

division evaluation value Example 1 2.17 Example 2 2.38 Example 3 2.30 Example 4 2.42 Example 5 2.33 Example 6 2.39 Example 7 2.38 Example 8 2.45 Example 9 1.51 Example 10 1.74 Example 11 1.67 Example 12 1.81 Example 13 1.73 Example 14 1.66 Example 15 1.72 Example 16 1.85 Example 17 1.25 Example 18 1.39 Example 19 1.67 Example 20 0.67 Comparative Example 1 4.30 Comparative Example 2 4.08 Comparative Example 3 4.21 Comparative Example 4 4.55 Comparative Example 5 4.45 Comparative Example 6 4.15 Comparative Example 7 4.11 Comparative Example 8 4.27 Comparative Example 9 4.54 Comparative Example 10 4.48 control group 4.60

Referring to Table 5, the composition containing lactic acid bacteria effectively improved vascular disease, and when two or more lactic acid bacteria were mixed (Examples 9 to 18), the effect of alleviating vascular disease was further improved.

In particular, in Examples 19 and 20, in which a skin softener was added, the effect of improving keratinoma was significantly improved compared to the case where only lactic acid bacteria were applied.

On the other hand, in the comparative example in which yeast, Bacillus subtilis, Chrysanthemum bacillus, and Actinomycete, rather than lactic acid bacteria, were applied, almost no effect was observed in alleviating H. tuberculosis.

The above results suggest that lactic acid bacteria can effectively relieve keratinoma by acting on the skin, and that the effect of relieving keratinoma can be further improved when lactic acid bacteria are mixed or applied together with a skin emollient.

Experimental Example 4: Verification evaluation of skin improvement effect

The evaluations of Experimental Examples 2 and 3 were repeated by varying the species of lactic acid bacteria in the examples.

Lactobacillus genus, Streptococcus genus, Lactococcus genus, Enterococcus genus, Pediococcus genus, Leuconostoc genus, Weissella genus and Bifidobacterium ( Bifidobacterium ) strains were selected, and the above experiment was repeated.

As a result of the evaluation, each strain belonging to lactic acid bacteria was equivalent to or slightly different from the strain in the example, but significantly alleviated the symptoms of milia and ductoma.

The above results suggest that lactic acid bacteria can commonly exhibit an improvement effect on milia and ductal tumors due to their biological characteristic of producing lactic acid.

The description of the present invention described above is for illustrative purposes, and those skilled in the art will understand that the present invention can be easily modified into other specific forms without changing the technical idea or essential features of the present invention. will be. Therefore, the embodiments described above should be understood in all respects as illustrative and not restrictive. For example, each component described as single may be implemented in a distributed manner, and similarly, components described as distributed may also be implemented in a combined form.

The scope of the present invention is indicated by the patent claims described below, and all changes or modified forms derived from the meaning and scope of the claims and their equivalent concepts should be construed as being included in the scope of the present invention.

Claims (8)

Contains lactic acid bacteria and urea as active ingredients,
The lactic acid bacteria include Lactobacillus plantarum, Streptococcus thermophilus, Lactococcus lactis, Enterococcus faecalis, Pediococcus pentosaceus, Leuconostoc mesenteroids, Vicella coriensis, and Bifidobacterium bifi. A cosmetic composition for improving milia or keratoma, consisting of a mixture of two or more strains selected from the group consisting of Doom strains. delete delete delete delete Contains lactic acid bacteria and urea as active ingredients,
The lactic acid bacteria include Lactobacillus plantarum, Streptococcus thermophilus, Lactococcus lactis, Enterococcus faecalis, Pediococcus pentosaceus, Leuconostoc mesenteroids, Vicella coriensis, and Bifidobacterium bifi. A composition for external application for skin for improving milia or keratoma, consisting of a mixture of two or more strains selected from the group consisting of Doom strains.
delete delete